What Happened
Novo Nordisk A/S (NYSE:NVO) stock has experienced a significant decline, trading 14.9% lower at $40.38 following the results of an 84-week trial for its next-generation weight loss drug, CagriSema. The trial revealed that CagriSema was less effective than Eli Lilly’s (LLY) tirzepatide, the active ingredient in Mounjaro and Zepbound. At one point, NVO shares slipped to a four-year low of $39.97, marking a potential fifth consecutive loss and the largest single-day percentage drop since July. Over the past year, the stock has decreased by more than 54%.
Why It Matters
The disappointing trial results for CagriSema have raised concerns about Novo Nordisk’s competitive position in the weight-loss drug market. The average weight loss for patients taking CagriSema was reported at 23%, compared to 25.5% for those taking tirzepatide. This outcome signals that Novo Nordisk may be falling behind its rival, Eli Lilly, which has seen accelerating sales. The divergence in stock performance between the two companies has become more pronounced, with Eli Lilly’s stock gaining while Novo Nordisk’s continues to decline.
What’s Next
Despite the setback, Novo Nordisk plans to pursue approval for CagriSema as a combination therapy later this year. Options traders appear to be leaning bullish, as indicated by a high call/put volume ratio. Today’s options activity has seen significant trading, with 72,000 calls and 57,000 puts exchanged, suggesting that traders are still optimistic about potential future performance. Investors will be closely monitoring upcoming earnings and regulatory milestones to gauge the company’s recovery prospects.
